Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Diabetes
•
Endocrinology
•
Obesity Medicine
•
General Endocrinology
Should we be using body fat percentage instead of BMI for determining patients' risk of metabolic syndrome?
https://pubmed.ncbi.nlm.nih.gov/38747476/
Related Questions
Do you use the homeostatic model assessment (HOMA) to assess for insulin resistance and change your clinical management of patients?
Do you recommend the use of GLP1 R agonist therapy in patients with T1DM for weight loss?
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
Is there a role for use of GLP1 R agonist or dual agonist therapy for management of post bariatric hypoglycemia and dumping syndrome?
How do you adjust your HbA1c goal for managing diabetes in elderly patients with multiple chronic illnesses but no limitations in performing self-care tasks?
What is the typical timeline for remission of autoimmune hypoglycemia?
Should we recommend SGLT2i initiation at discharge to all patients hospitalized with acute myocardial infarction?
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
How do you counsel patients on the use of compounded weight loss medications?
Does norethindrone suppress FSH, LH completely?
